tuberculosis, pulmonary

Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

---

Study Counts

Type	Study_count
Total_Studies	137
interventional	103
Observational	24
Registry	10

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type	Study_Count
Drug	54
Drug|placebo	15
Other	8
Biological	4
Biological|placebo	3
Dietary Supplement|Drug	3
Procedure	3
Diagnostic Test	2
Dietary Supplement	2
Drug|Procedure|Radiation	2
Behavioral	1
Behavioral|Device|Other	1
Device	1
Dietary Supplement|Other	1
Drug|Other	1
Drug|Procedure	1
Radiation	1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country	Study_Count
South Africa	21
United States	9
India	7
China	5
NA	4
Brazil	3
Korea, Republic of	3
South Africa|Tanzania	3
Tanzania	3
Bangladesh	2
Ethiopia	2
Indonesia	2
Malawi	2
Switzerland	2
Belarus|South Africa|Uzbekistan	1
Belgium	1
Botswana|Guinea|Mexico|Nepal|Pakistan|Peru|Uganda	1
Brazil|Georgia|Malaysia|Philippines|Russian Federation|South Africa|Tanzania|Uganda	1
China|India|Kenya|Malaysia|Mexico|South Africa|Tanzania|Thailand|Zambia	1
China|South Africa	1
Colombia	1
France	1
Georgia|India|Kazakhstan|Lesotho|Pakistan|Peru|South Africa	1
Georgia|Kenya|Malaysia|Philippines|South Africa|Tanzania|Uganda|Zambia	1
Georgia|Moldova, Republic of|Russian Federation|South Africa	1
Germany	1
Ghana	1
Guinea-Bissau	1
Indonesia|Peru|Romania	1
Indonesia|Philippines|Singapore|Thailand	1
Japan	1
Netherlands	1
Pakistan	1
Peru|South Africa	1
Peru|Vietnam	1
Philippines|Singapore|Uganda	1
Russian Federation	1
Singapore	1
South Africa|Tanzania|Uganda	1
Taiwan	1
Uganda	1
United Kingdom	1
United States|Brazil	1
United States|Brazil|Canada|South Africa|Spain|Uganda	1
United States|Canada	1
United States|Canada|South Africa|Uganda	1
United States|China|Egypt|Estonia|Japan|Korea, Republic of|Latvia|Peru|Philippines	1
United States|South Africa|Uganda	1
Zambia	1

Sites per Study

Site_count	Study_Count
1	52
2	15
3	7
4	4
5	1
6	3
7	3
8	2
9	1
10	3
11	1
12	1
14	1
17	1
20	1
21	1
23	2
26	2
29	1
47	1

Phase

Phase	Study_Count
Phase 2	41
N/A	21
Phase 3	18
Phase 1	11
Phase 4	5
Phase 1/Phase 2	4
Phase 2/Phase 3	3

Number of Arms

Number_of_Arms	Count_of_Studies
1	6
2	34
3	15
4	11
5	8
6	9
7	1
8	4
9	1
10	2
12	1
13	1
19	1
NA	9

Enrollment Metrics by Phase

Measure	N.A	Phase.1	Phase.1.Phase.2	Phase.2	Phase.2.Phase.3	Phase.3	Phase.4
Min.	24.000	30.00000	31.00	24.0000	455.0000	109.0000	100.0
1st Qu.	160.000	32.00000	60.25	58.0000	542.5000	258.5000	172.0
Median	264.000	44.00000	73.50	88.0000	630.0000	528.5000	300.0
Mean	1207.333	49.63636	75.75	196.1951	661.6667	636.0556	7250.8
3rd Qu.	572.000	63.00000	89.00	240.0000	765.0000	950.0000	924.0
Max.	11337.000	91.00000	125.00	1200.0000	900.0000	1931.0000	34758.0

Trial Group Type

group_type	Group_Count
Experimental	212
Active Comparator	87
Placebo Comparator	50
No Intervention	11
NA	9
Other	8
Sham Comparator	1

Intervention Model

intervention_model	Study_Count
Parallel Assignment	76
Single Group Assignment	9
Sequential Assignment	8
Factorial Assignment	5
NA	4
Crossover Assignment	1

Primary Purpose

primary_purpose	Study_Count
Treatment	81
Diagnostic	10
Prevention	5
Supportive Care	3
Health Services Research	2
Other	1
NA	1

Observational Studies

Studies by Country

Country	Study_Count
Korea, Republic of	3
United States	3
India	2
Taiwan	2
Belarus|Georgia|India|South Africa	1
Brazil	1
China	1
Ethiopia	1
Ethiopia|Gambia|Germany|Namibia|Netherlands|South Africa|Uganda|United Kingdom	1
Ethiopia|India	1
Hong Kong	1
Indonesia	1
Italy	1
Mali	1
Moldova, Republic of	1
NA	1
Peru	1
Romania	1

Sites per Study

Site_count	Study_Count
1	16
2	2
3	1
4	1
6	1
10	2
20	1

Enrollment Metrics

Measure	Observational
Min	10.0000
1st Qu	55.0000
Median	318.0000
Mean	438.3043
3rd Qu	680.0000
Max	1666.0000

Observation Model

observational_model	Study_Count
Cohort	9
Case-Only	5
Case-Control	3
NA	3
Case Control	2
Other	2

Time Perspective

time_perspective	Study_Count
Prospective	16
Cross-Sectional	6
Other	1
Retrospective	1

Registries

Studies by Country

Country	Study_Count
Korea, Republic of	3
China	1
France	1
Gambia|Mozambique|South Africa|Tanzania	1
Georgia	1
Italy	1
NA	1
Netherlands	1

Sites per Study

Site_count	Study_Count
1	8
3	1
4	1

Enrollment Metrics

Measure	Registries
Min	8.00
1st Qu	91.75
Median	224.50
Mean	440.90
3rd Qu	725.00
Max	1600.00

Registry Model

observational_model	Study_Count
Cohort	7
Case-Only	1
Case Control	1
Other	1

Time Perspective

time_perspective	Study_Count
Prospective	9
Other	1

Follow-up

target_duration	Study_Count
2 Months	2
2 Years	2
6 Months	2
1 Week	1
10 Years	1
12 Months	1
8 Years	1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT03338621	Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients	https://ClinicalTrials.gov/show/NCT03338621	Active, not recruiting	Global Alliance for TB Drug Development	2020-04-30
NCT03302949	Treating Tuberculosis Wasting With a High-protein Supplement	https://ClinicalTrials.gov/show/NCT03302949	Active, not recruiting	University of Aarhus	2020-08-31
NCT03281226	RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection	https://ClinicalTrials.gov/show/NCT03281226	Recruiting	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	2019-06-30
NCT03199339	A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371	https://ClinicalTrials.gov/show/NCT03199339	Completed	Global Alliance for TB Drug Development	2018-07-08
NCT03199313	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid	https://ClinicalTrials.gov/show/NCT03199313	Completed	Global Alliance for TB Drug Development	2017-12-16
NCT03174184	Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB	https://ClinicalTrials.gov/show/NCT03174184	Recruiting	Johns Hopkins University	2021-07-31
NCT03160638	Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT03160638	Recruiting	University Medical Center Groningen	2020-02-01
NCT03086486	Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)	https://ClinicalTrials.gov/show/NCT03086486	Active, not recruiting	Global Alliance for TB Drug Development	2020-12-31
NCT02961569	Comparison Between Two Strategies for the Diagnosis of TB	https://ClinicalTrials.gov/show/NCT02961569	Completed	Hopital Lariboisière	2017-04-30
NCT02912832	Prospective Assessment of TBDx Feasibility	https://ClinicalTrials.gov/show/NCT02912832	Completed	Foundation for Innovative New Diagnostics, Switzerland	2015-03-31
NCT02836483	A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK	https://ClinicalTrials.gov/show/NCT02836483	Completed	LegoChem Biosciences, Inc	2019-07-01
NCT02774993	Doxycycline in Human Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT02774993	Completed	National University Hospital, Singapore	2017-06-30
NCT02754765	Evaluating Newly Approved Drugs for Multidrug-resistant TB	https://ClinicalTrials.gov/show/NCT02754765	Recruiting	Médecins Sans Frontières, France	2020-09-30
NCT02589782	Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)	https://ClinicalTrials.gov/show/NCT02589782	Recruiting	Medecins Sans Frontieres, Netherlands	2020-06-30
NCT02583048	Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT02583048	Active, not recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	2019-01-07
NCT02581527	A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT02581527	Recruiting	St George’s, University of London	2021-01-31
NCT02558842	Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance	https://ClinicalTrials.gov/show/NCT02558842	Completed	Hospital de Clinicas de Porto Alegre	2015-09-30
NCT02554318	Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia	https://ClinicalTrials.gov/show/NCT02554318	Completed	University of Giessen	2015-02-28
NCT02481726	68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT	https://ClinicalTrials.gov/show/NCT02481726	Completed	Xijing Hospital	2014-10-31
NCT02381470	Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers	https://ClinicalTrials.gov/show/NCT02381470	Completed	National University Hospital, Singapore	2019-09-28
NCT02371681	NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis	https://ClinicalTrials.gov/show/NCT02371681	Completed	National Institutes of Health Clinical Center (CC)	2017-09-01
NCT02349841	Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT02349841	Completed	TASK Applied Science	2014-12-31
NCT02342886	Shortening Treatment by Advancing Novel Drugs	https://ClinicalTrials.gov/show/NCT02342886	Completed	Global Alliance for TB Drug Development	2018-01-31
NCT02333799	A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT02333799	Active, not recruiting	Global Alliance for TB Drug Development	2019-01-14
NCT02313610	Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT02313610	Completed	Shanghai University of Traditional Chinese Medicine	2013-03-31
NCT02279875	A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)	https://ClinicalTrials.gov/show/NCT02279875	Completed	Global Alliance for TB Drug Development	2016-11-28
NCT02256696	Assessing PA-824 for Tuberculosis (the APT Trial)	https://ClinicalTrials.gov/show/NCT02256696	Recruiting	Johns Hopkins University	2020-09-30
NCT02219945	ENOSE in Pulmonary Tuberculosis in Yogyakarta	https://ClinicalTrials.gov/show/NCT02219945	Completed	University Medical Center Groningen	2014-12-31
NCT02193776	A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.	https://ClinicalTrials.gov/show/NCT02193776	Completed	Global Alliance for TB Drug Development	2016-02-08
NCT02153528	Optimization of the TB Treatment Regimen Cascade	https://ClinicalTrials.gov/show/NCT02153528	Completed	Damien Foundation	2017-08-01
NCT02106039	Pulmonary Tuberculosis Patients With Diabetes Mellitus	https://ClinicalTrials.gov/show/NCT02106039	Completed	Universitas Padjadjaran	2017-02-21
NCT02053129	Evaluation of PTB Screening in ANC in Lusaka, Zambia	https://ClinicalTrials.gov/show/NCT02053129	Completed	University of North Carolina, Chapel Hill	2012-10-31
NCT01927159	Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers	https://ClinicalTrials.gov/show/NCT01927159	Completed	IDRI	2015-07-31
NCT01785186	Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design	https://ClinicalTrials.gov/show/NCT01785186	Completed	Ludwig-Maximilians - University of Munich	2014-09-30
NCT01698476	Immune Reconstitution in Tuberculosis Disease	https://ClinicalTrials.gov/show/NCT01698476	Completed	Karolinska Institutet	2015-08-31
NCT01691534	Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)	https://ClinicalTrials.gov/show/NCT01691534	Completed	Global Alliance for TB Drug Development	2013-04-30
NCT01618422	Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou	https://ClinicalTrials.gov/show/NCT01618422	Completed	Chinese University of Hong Kong	2013-02-28
NCT01599897	Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers	https://ClinicalTrials.gov/show/NCT01599897	Completed	IDRI	2014-05-31
NCT01580007	Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)	https://ClinicalTrials.gov/show/NCT01580007	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	2014-12-31
NCT01517022	Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT01517022	Completed	All India Institute of Medical Sciences, New Delhi	2016-09-30
NCT01498419	Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)	https://ClinicalTrials.gov/show/NCT01498419	Completed	Global Alliance for TB Drug Development	2013-04-30
NCT01392911	Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB	https://ClinicalTrials.gov/show/NCT01392911	Completed	Radboud University	2018-07-31
NCT01363765	Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil	https://ClinicalTrials.gov/show/NCT01363765	Completed	Ataulpho de Paiva Foundation	2012-10-31
NCT04433195	Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT04433195	Recruiting	Taipei Medical University WanFang Hospital	2021-04-30
NCT04122404	POC Strategies to Improve TB Care in Advanced HIV Disease	https://ClinicalTrials.gov/show/NCT04122404	Recruiting	University of Southern Denmark	2021-08-15
NCT04044001	BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)	https://ClinicalTrials.gov/show/NCT04044001	Recruiting	Ludwig-Maximilians - University of Munich	2020-10-31
NCT03967353	Study on the Management Model of “Home Treatment” for Tuberculosis Patients	https://ClinicalTrials.gov/show/NCT03967353	Recruiting	Beijing Chest Hospital	2022-03-31
NCT03882177	StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis	https://ClinicalTrials.gov/show/NCT03882177	Active, not recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	2020-12-31
NCT03851159	Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota	https://ClinicalTrials.gov/show/NCT03851159	Recruiting	University of Stellenbosch	2021-12-31
NCT03776500	Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing	https://ClinicalTrials.gov/show/NCT03776500	Recruiting	Innovative Medicines for Tuberculosis	2019-09-30
NCT03758612	A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults	https://ClinicalTrials.gov/show/NCT03758612	Completed	Global Alliance for TB Drug Development	2020-03-14
NCT03702738	Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT03702738	Recruiting	The Aurum Institute NPC	2020-10-30
NCT03678688	A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT03678688	Recruiting	Otsuka Pharmaceutical Development & Commercialization, Inc.	2021-06-30
NCT03590600	A Single Ascending Dose Study of BTZ043	https://ClinicalTrials.gov/show/NCT03590600	Completed	Ludwig-Maximilians - University of Munich	2018-08-14
NCT03561753	Pilot Clinical Trial of PRS TB Regimen I - Phase II	https://ClinicalTrials.gov/show/NCT03561753	Enrolling by invitation	Shanghai Pulmonary Hospital, Shanghai, China	2019-12-31
NCT03557281	An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT03557281	Recruiting	GlaxoSmithKline	2022-04-29
NCT03519425	A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi	https://ClinicalTrials.gov/show/NCT03519425	Active, not recruiting	Liverpool School of Tropical Medicine	2019-12-31
NCT03512249	Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence	https://ClinicalTrials.gov/show/NCT03512249	Recruiting	Aeras	2022-04-06
NCT03478033	Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis	https://ClinicalTrials.gov/show/NCT03478033	Recruiting	Shanghai Public Health Clinical Center	2020-06-01
NCT03474198	Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis	https://ClinicalTrials.gov/show/NCT03474198	Recruiting	University College, London	2022-03-12
NCT03423030	Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation	https://ClinicalTrials.gov/show/NCT03423030	Completed	Innovative Medicines for Tuberculosis	2018-03-28
NCT01242592	Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT01242592	Completed	NMP Medical Research Institute	NA
NCT01218217	Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB	https://ClinicalTrials.gov/show/NCT01218217	Completed	Ludwig-Maximilians - University of Munich	2011-09-30
NCT01215851	Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)	https://ClinicalTrials.gov/show/NCT01215851	Completed	Global Alliance for TB Drug Development	2011-05-31
NCT01215110	Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)	https://ClinicalTrials.gov/show/NCT01215110	Completed	Global Alliance for TB Drug Development	2010-08-31
NCT01162486	Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers	https://ClinicalTrials.gov/show/NCT01162486	Completed	Johns Hopkins University	2011-02-28
NCT01130311	Replacement of Vitamin D in Patients With Active Tuberculosis	https://ClinicalTrials.gov/show/NCT01130311	Completed	Aga Khan University	2010-04-30
NCT01043575	High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis	https://ClinicalTrials.gov/show/NCT01043575	Completed	Centers for Disease Control and Prevention	2010-05-31
NCT01011543	Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT01011543	Completed	Centre Hospitalier Universitaire Saint Pierre	2015-12-31
NCT00944021	Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)	https://ClinicalTrials.gov/show/NCT00944021	Completed	Global Alliance for TB Drug Development	2010-01-31
NCT00939419	The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis	https://ClinicalTrials.gov/show/NCT00939419	Completed	University of Leeds	2006-12-31
NCT00933790	Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00933790	Completed	Tuberculosis Research Centre, India	2016-12-31
NCT00864383	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00864383	Completed	Global Alliance for TB Drug Development	2013-10-31
NCT02465216	Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion	https://ClinicalTrials.gov/show/NCT02465216	Completed	IDRI	2017-01-31
NCT00814671	Study of Daily Rifapentine for Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00814671	Completed	Johns Hopkins University	2013-06-30
NCT01945905	Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia	https://ClinicalTrials.gov/show/NCT01945905	Completed	Fundación FES	2014-08-31
NCT00801606	Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00801606	Completed	All India Institute of Medical Sciences, New Delhi	2012-06-30
NCT03722472	Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults	https://ClinicalTrials.gov/show/NCT03722472	Active, not recruiting	IDRI	2020-03-31
NCT03044158	GeneXpert Performance Evaluation for Linkage to Tuberculosis Care	https://ClinicalTrials.gov/show/NCT03044158	Active, not recruiting	University of California, San Francisco	2020-03-01
NCT02821832	Using Biomarkers to Predict TB Treatment Duration	https://ClinicalTrials.gov/show/NCT02821832	Recruiting	National Institutes of Health Clinical Center (CC)	2021-12-31
NCT00760149	Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00760149	Completed	Radboud University	2013-09-30
NCT00727844	Linezolid to Treat Extensively-Drug Resistant Tuberculosis	https://ClinicalTrials.gov/show/NCT00727844	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2012-10-31
NCT00694629	TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment	https://ClinicalTrials.gov/show/NCT00694629	Completed	Centers for Disease Control and Prevention	2013-06-30
NCT00685360	A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)	https://ClinicalTrials.gov/show/NCT00685360	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.	2010-06-30
NCT00677339	L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)	https://ClinicalTrials.gov/show/NCT00677339	Completed	Menzies School of Health Research	2010-02-28
NCT00567840	PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00567840	Completed	Global Alliance for TB Drug Development	2007-12-31
NCT00495339	MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00495339	Completed	Sanofi	2008-04-30
NCT00425113	Metronidazole for Pulmonary Tuberculosis (South Korea)	https://ClinicalTrials.gov/show/NCT00425113	Completed	National Institutes of Health Clinical Center (CC)	2012-10-31
NCT00419068	Trial of Adjunctive Vitamin D in Tuberculosis Treatment	https://ClinicalTrials.gov/show/NCT00419068	Completed	Barts & The London NHS Trust	2009-09-30
NCT00401271	Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00401271	Completed	Otsuka Frankfurt Research Institute GmbH	NA
NCT00396084	Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00396084	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2007-11-23
NCT00366470	A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients	https://ClinicalTrials.gov/show/NCT00366470	Completed	Christian Medical College, Vellore, India	2012-05-31
NCT00341328	Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.	https://ClinicalTrials.gov/show/NCT00341328	Completed	Ministry of Science and Technology, India	2011-10-31
NCT00311298	Nutrition, Diabetes and Pulmonary TB/HIV	https://ClinicalTrials.gov/show/NCT00311298	Completed	University of Copenhagen	2009-03-31
NCT00298870	Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)	https://ClinicalTrials.gov/show/NCT00298870	Completed	Osaka University	NA
NCT00265226	Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients	https://ClinicalTrials.gov/show/NCT00265226	Completed	Ministry of Science and Technology, India	2010-12-31
NCT00140309	TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment	https://ClinicalTrials.gov/show/NCT00140309	Completed	Centers for Disease Control and Prevention	NA
NCT00057434	Vitamin A Therapy for Tuberculosis	https://ClinicalTrials.gov/show/NCT00057434	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	NA
NCT00023335	TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis	https://ClinicalTrials.gov/show/NCT00023335	Completed	Centers for Disease Control and Prevention	NA
NCT00000796	A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.	https://ClinicalTrials.gov/show/NCT00000796	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	NA
NCT00000778	A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin	https://ClinicalTrials.gov/show/NCT00000778	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	NA
NCT00001407	Interferon Gamma for Drug Resistant Tuberculosis	https://ClinicalTrials.gov/show/NCT00001407	Completed	National Institutes of Health Clinical Center (CC)	NA
NCT00004444	Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00004444	Completed	FDA Office of Orphan Products Development	NA

Observational Studiess

#If less then 500 studies

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT03072576	Accuracy and Feasibility of Xpert Ultra	https://ClinicalTrials.gov/show/NCT03072576	Completed	Foundation for Innovative New Diagnostics, Switzerland	2017-03-31
NCT02984579	Line Probe Assay Evaluation Study	https://ClinicalTrials.gov/show/NCT02984579	Completed	Foundation for Innovative New Diagnostics, Switzerland	2016-01-31
NCT02758236	Tuberculosis Research of INA-RESPOND On Drug Resistance	https://ClinicalTrials.gov/show/NCT02758236	Active, not recruiting	Ina-Respond	2021-12-31
NCT02736864	Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae	https://ClinicalTrials.gov/show/NCT02736864	Completed	Federal University of Uberlandia	2017-10-31
NCT02653404	IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection	https://ClinicalTrials.gov/show/NCT02653404	Recruiting	University of Siena	2019-04-30
NCT02382107	A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania	https://ClinicalTrials.gov/show/NCT02382107	Completed	Ludwig-Maximilians - University of Munich	2016-05-31
NCT01301144	Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT01301144	Completed	National Institutes of Health Clinical Center (CC)	NA
NCT01866579	Early Retinal Nerve Fiber Layer Change of Ethambutol Optic Neuropathy by Optical Coherence Tomography	https://ClinicalTrials.gov/show/NCT01866579	Completed	Yonsei University	2014-05-31
NCT03350048	Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB	https://ClinicalTrials.gov/show/NCT03350048	Enrolling by invitation	University of Stellenbosch	2019-06-30
NCT01587469	Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects	https://ClinicalTrials.gov/show/NCT01587469	Completed	Cepheid	2014-02-21
NCT01364324	Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients	https://ClinicalTrials.gov/show/NCT01364324	Recruiting	National Cancer Center, Korea	2020-06-30
NCT04434976	Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China	https://ClinicalTrials.gov/show/NCT04434976	Completed	Huashan Hospital	2019-11-02
NCT04342598	Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India	https://ClinicalTrials.gov/show/NCT04342598	Recruiting	Harvard School of Public Health	2020-09-30
NCT03728725	Xpert MTB/XDR Clinical Evaluation Trial	https://ClinicalTrials.gov/show/NCT03728725	Recruiting	Foundation for Innovative New Diagnostics, Switzerland	2020-07-31
NCT03712709	Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test	https://ClinicalTrials.gov/show/NCT03712709	Recruiting	Foundation for Innovative New Diagnostics, Switzerland	2019-09-30
NCT01002170	Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament	https://ClinicalTrials.gov/show/NCT01002170	Completed	Taipei Medical University WanFang Hospital	2009-06-30
NCT00834353	Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis	https://ClinicalTrials.gov/show/NCT00834353	Completed	Maulana Azad Medical College	2008-03-31
NCT01379066	Tuberculosis Volatile Organic Compounds	https://ClinicalTrials.gov/show/NCT01379066	Completed	Landon Pediatric Foundation	2009-12-31
NCT00803322	Improving Community Based Tuberculosis Care in Ethiopia	https://ClinicalTrials.gov/show/NCT00803322	Completed	University of Bergen	2007-09-30
NCT03271567	Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients	https://ClinicalTrials.gov/show/NCT03271567	Completed	Chinese University of Hong Kong	2019-07-31
NCT00772408	Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	https://ClinicalTrials.gov/show/NCT00772408	Completed	Chang Gung Memorial Hospital	2009-11-30
NCT00567151	Co-Infection of NTM in Patients With Smear Positive Pulmonary TB	https://ClinicalTrials.gov/show/NCT00567151	Completed	Seoul National University Hospital	2008-12-31
NCT00212550	Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb	https://ClinicalTrials.gov/show/NCT00212550	Completed	NYU Langone Health	2010-02-28
NCT00054769	Diagnosing Tuberculosis in HIV Infected Children in Peru	https://ClinicalTrials.gov/show/NCT00054769	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	2007-02-28

Registries

#If less then 500 registries

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT03251196	TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB	https://ClinicalTrials.gov/show/NCT03251196	Recruiting	The Aurum Institute NPC	2022-06-30
NCT02715271	Study of TB Lesions Obtained in Therapeutical Surgery	https://ClinicalTrials.gov/show/NCT02715271	Active, not recruiting	Fundació Institut Germans Trias i Pujol	2020-07-31
NCT02527486	Seoul National University Airway Registry	https://ClinicalTrials.gov/show/NCT02527486	Recruiting	Seoul National University Hospital	2021-12-31
NCT02331056	Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?	https://ClinicalTrials.gov/show/NCT02331056	Completed	Samsung Medical Center	2015-06-30
NCT04236349	Tuberculosis Cohort in the North of Paris	https://ClinicalTrials.gov/show/NCT04236349	Recruiting	Assistance Publique - Hôpitaux de Paris	2020-01-31
NCT04079400	Microbiome in Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases, Lung Cancer and Hemoptysis	https://ClinicalTrials.gov/show/NCT04079400	Completed	Gachon University Gil Medical Center	2018-10-30
NCT04074369	Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects	https://ClinicalTrials.gov/show/NCT04074369	Recruiting	Huashan Hospital	2019-10-30
NCT04055584	PCR Techniques of Dried Sputum Using a Spotcard	https://ClinicalTrials.gov/show/NCT04055584	Recruiting	University Medical Center Groningen	2020-11-30
NCT03416309	Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response	https://ClinicalTrials.gov/show/NCT03416309	Recruiting	University of Turin, Italy	2021-02-28
NCT03822156	Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort	https://ClinicalTrials.gov/show/NCT03822156	Completed	University of Ulsan	2018-06-30